Welcome & Introduction
Nigel Russell, Founder, Precision Medicine Leaders’ Summits, The Journal of Precision Medicine
Pharmacogenomics and Disparities: From Clinical Trials to Individualized Medicine
Howard McLeod, PharmD, FASCO, FCCP, Medical Director, Geriatric Oncology Consortium and Professor, University of South Florida
The processes for developing drugs has streamlined to allow for global recruitment of patients and understanding of the genomic context on which a drug is acting. However, this has resulted in ‘data deserts’ where little or no information is available for understanding the safety and efficacy in many populations. There is also differences in drug benefit or adverse drug events that are observed across groups within a populations. There is an opportunity to bring equity to drug development and routine use of medications, but only if we are purposeful now.
Pharmacogenomics in Community Dwelling Older Adults
Elvin Price, PharmD, PhD, Victor A. Yanchick Associate Professor and Director of the Geriatric Pharmacotherapy at the Virginia Commonwealth University School of Pharmacy and Co-Director of the Institute for Inclusion, Inquiry and Innovation (iCubed) Health and Wellness in Aging Core
Older community dwelling adults experience more adverse drug events than any other subgroup of adults. Specifically, older adults are most likely to visit emergency departments, become hospitalized, or suffer premature death due to adverse drug events. There is an immediate need for medication safety interventions that can make large-scale improvements for older adults. Pharmacogenomic approaches may prove useful for reducing medication-related adverse events for older community dwelling adults. However, we must recruit diverse cohorts of older adults to evaluate this hypothesis. I will discuss approaches that were used to create a longitudinal pharmacogenomics study within an ethnically diverse cohort of community dwelling older adults
The Power and the Promise: Making Pharmacogenomics Implementation Effective and Easy
Martin Dawes, PhD, Co-Founder and Chief Scientific Officer, GenXys Health Care Systems
New clinical tools are being offered to address a critical medical need for personalized health care in primary care. This includes decision support tools that predict if a patient will experience an adverse event, require a certain dosage, or benefit more from a different medication because of interactions including how they metabolize a drug. Implementing PGx can, and should, be a straightforward and efficient process. This session will focus on the four steps that make precision prescribing accessible for physicians, pharmacists and other healthcare providers.
The Importance of Germline Pharmacogenomic Testing for Oncology Patients
Moderator: Julie Ceno-England, MD, Head, Medical Affairs; Interim Chief Medical Officer, OneOme
Panelists: Pashtoon Kasi, MD, MS, Director Colon Cancer Research, Weill Cornell Medicine; Precision Medicine Director, Liquid Biopsy Research, Englander Institute of Precision Medicine; Adrijana Kekic, PharmD, Pharmacogenomics Clinical Pharmacy Specialist, Assistant Program Director (APD), Community-Based Pharmacy Residency; APD Outpatient Pharmacy Education, Mayo Clinic, Arizona (MCA); David Stenehjem, PharmD, BCOP, Associate Professor, Associate Department Head, Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, College of Pharmacy;
Through this panel discussion, attendees will learn the value of germline pharmacogenomic testing in oncology. Expert panelists from across the healthcare ecosystem, who have experience implementing and leading pharmacogenomic programs, will share their perspectives and insights in what promises to be an impactful and meaningful discussion. Topics will include:
• The value of PGx testing for oncology patients
• Strategies for program implementation
• Considerations for oncology program design
Fireside Chat – Implementing Comprehensive Pharmacogenomics: Lessons Learned
Kristine Ashcraft, MBA, Medical Affairs Director, Pharmacogenomics, Invitae; Burns C. Blaxall, PhD, FACC, FAHA, FISHR, FAPS, Executive Director, Precision Medicine, The Christ Hospital Health Network
The Christ Hospital Health Network has just launched a comprehensive precision medicine program that includes one of the largest pharmacogenomics studies ever undertaken. Join Burns and Kristine for a fireside chat to discuss lessons learned about the importance of implementation science including executive buy-in, embedded pharmacists, EHR-integrated CDST, levering tools such as chatbots, and incorporating drug and gene interactions in a single action-based guidance.
Filling the Gaps in PGx Awareness
Moderator: Kandace Schuft, PharmD, Senior Clinical Content Specialist, Pharmacogenomics, Wolters Kluwer
Panelists: Bernard Esquivel, MD, PhD, MHA, Chief Medical Officer, GenXys Health Care Systems; Jennifer Hockings, PharmD, PhD, Pharmacogenomics Clinical Specialist, Cleveland Clinic, Department of Pharmacy and Center for Personalized Genetic Healthcare (CPGH)
Despite significant advances in precision health technology, personalized care delivery relies on clinicians having access to all of the information to choose the right treatment for the individual patient. Availability of information like pharmacogenomic (PGx) test results and guidelines in the workflow, without placing added burden on the clinician, is imperative. Ensuring both students and practicing physicians and pharmacists are educated on pharmacogenomics is a needed focus. Only about 200 new pharmacists per year are focused on PGx; this isn’t enough. How do we fill that gap?
This panel of experts will discuss how to set up pharmacists for success and maximize the use of PGx testing to ensure the safest, most effective, personalized care for patients.
Improving Patient Outcomes Through the Integration of Pharmacogenomic Testing into Comprehensive Medication Management Care Models
Moderator: Katherine H. Capps, Co-founder and Executive Director, GTMRx Institute
Panelists: Ghada Elnashar, PharmD, MS, Medical Science Liaison, OneOme; Anthony P. Morreale, PharmD, MBA, BCPS, FASHP, Associate Chief Consultant, Clinical Pharmacy and Policy, Department of Veterans Affairs Pharmacy Benefits Management, VA Central Office; Jacques Turgeon, BPharm, PhD, Chief Scientific Officer and Chief Executive Officer, TRHC Precision Pharmacotherapy, Research and Development Institute
The role of pharmacogenomics in the clinical setting is shifting from a reactive testing approach toward a preemptive model. Since many clinicians have embraced comprehensive medication management (CMM), the goal of this panel is to educate health care professionals on the value of precision medicine and pharmacogenomic testing services in CMM care models. We will also explore methods for implementation, reimbursement opportunities and present evidence to support its role in mitigating polypharmacy and optimizing medication regimens, patient outcomes and cost savings.
Keynote – Pharmacogenomics In the Precision Medicine Era
Latha Palaniappan, MD, MS, Professor, Stanford University School of Medicine
There are known differences in drug metabolism, outcomes, and side effects across racial and ethnic groups, and not everyone responds to medications in the same way. A medicine that works well for others may not work well for you, resulting in significant side effects. In the US, adverse drug reactions cause a great number of hospitalizations and are a leading cause of death in hospitalized patients. Pharmacogenomics, or individualized drug therapy, can help us prevent dangerous drug reactions by pre-identifying at-risk patients. Pharmacogenomics analyses can study your unique genetic profile to determine which medications are likely to help you or harm you, before you even take them. Through this avenue of precision health, we can tailor medical care to every individual, and provide every patient with the right medication at the right dosage at the right time.